|
Mar 22
|
Veru Reschedules Annual Meeting of Shareholders
|
|
Mar 12
|
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
|
|
Feb 20
|
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
|
|
Dec 19
|
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
|
|
Dec 18
|
The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 29%
|
|
Dec 14
|
Veru Announces Pricing of Public Offering of Common Stock
|
|
Dec 13
|
Veru Announces Proposed Public Offering of Common Stock
|
|
Nov 8
|
Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates
|
|
Aug 11
|
What You Can Learn From Veru Inc.'s (NASDAQ:VERU) P/S
|
|
Aug 10
|
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
|
|
Aug 10
|
Veru Reports Fiscal 2023 Third Quarter Financial Results
|
|
Apr 12
|
Down -51.21% in 4 Weeks, Here's Why You Should You Buy the Dip in Veru Inc. (VERU)
|
|
Apr 11
|
Once COVID-19 Candidate, Veru's Sabizabulin Shows Encouraging Action In Animal Studies Against Poxvirus
|
|
Apr 11
|
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
|